Longevity Pharmacology in 2025: The Complete Drug Review
Beyond the lifestyle interventions with decades of human outcome data, a small but growing number of pharmacological agents are being seriously studied or used for longevity purposes. This is a systematic review of every major longevity drug currently in clinical use or late-stage trials: rapamycin, metformin, senolytics, SGLT2 inhibitors, GLP-1 agonists, acarbose, and aspirin — with honest evidence grading for each.
- The distinction between drugs with proven longevity benefits in humans and drugs with compelling mechanistic rationale and animal data is the most important framework for evaluating longevity pharmacology. As of 2025, no drug has been proven to extend healthy human lifespan in a randomized controlled trial. Several have been proven to reduce specific age-related disease endpoints.
- GLP-1 receptor agonists (semaglutide, tirzepatide) have the strongest recent human outcome data relevant to longevity: SELECT trial demonstrated 20 percent reduction in major cardiovascular events in overweight individuals without diabetes. Renal protective effects, hepatic fat reduction, and emerging data on neurodegeneration make this the most clinically impactful drug class of the decade for longevity-relevant outcomes.
- SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) have demonstrated renal protective and cardiovascular protective effects that appear partly independent of glucose lowering. Empagliflozin reduces heart failure hospitalization by 35 percent and slows eGFR decline — effects relevant to longevity independent of diabetes status.
- Rapamycin has the most compelling animal longevity data of any pharmacological agent — extending lifespan in mice even when started late — but lacks human longevity RCT evidence. It is used off-label in longevity medicine at doses (typically 2-6 mg/week intermittently) designed to inhibit mTORC1 while minimizing immunosuppression.
- Acarbose — an alpha-glucosidase inhibitor that blunts post-meal glucose absorption — significantly extended lifespan in the ITP mouse trial (by 17 percent in males) and is one of the most overlooked potential longevity drugs given its excellent safety record, low cost, and complementary mechanism to metformin.
The longevity pharmacology landscape in 2025 is simultaneously more developed and more constrained than popular discourse suggests. More developed because several drug classes have produced compelling human outcome data relevant to longevity; more constrained because no drug has yet been proven in a randomized controlled trial to extend healthy human lifespan as a primary endpoint. This review organizes the evidence systematically, separating what is established from what is promising from what is speculative.1
Tier 1: Proven Human Longevity-Relevant Outcomes
GLP-1 Receptor Agonists (semaglutide, tirzepatide, liraglutide): The most clinically impactful drug class of the 2020s for longevity-relevant outcomes. The SELECT trial established a 20 percent reduction in major adverse cardiovascular events with semaglutide 2.4 mg/week in overweight/obese adults without diabetes — the first cardiovascular outcome trial to show benefit in this population. LEADER (liraglutide) and SUSTAIN-6 (semaglutide) showed cardiovascular benefit in diabetics. FLOW (semaglutide) demonstrated significant renal protection. Emerging trial data suggests benefits for MASLD, heart failure, and potentially Alzheimer's disease (ongoing EVOKE trial).2
SGLT2 Inhibitors (empagliflozin, dapagliflozin, canagliflozin): Originally developed for type 2 diabetes, SGLT2 inhibitors have demonstrated cardiovascular and renal protective effects that appear to be partly independent of glucose lowering — suggesting mechanisms including AMPK activation, ketogenesis induction (producing mild therapeutic ketosis), and reduced tubular glucose reabsorption that reduces intraglomerular pressure. EMPEROR-Reduced and DAPA-HF trials established that empagliflozin and dapagliflozin significantly reduce heart failure hospitalizations and mortality in heart failure patients, including those without diabetes. CREDENCE and DAPA-CKD demonstrated renal protection. These agents are now being evaluated in non-diabetic populations with heart failure and CKD, expanding their applicability.
Tier 2: Compelling Human Data, Incomplete Longevity Evidence
Metformin: Covered extensively in article 6.4. The key update: the observational finding of metformin-treated diabetics outliving non-diabetic controls remains the most striking hint of longevity benefit. The TAME trial (results expected 2025-2026) is the definitive test. The exercise interference concern is clinically significant and should inform patient selection. The B12 depletion risk requires active monitoring.3
Low-dose aspirin: The aspirin longevity story has evolved significantly. The ASPREE trial (19,114 older adults without established cardiovascular disease) found that aspirin increased all-cause mortality slightly — primarily driven by increased cancer mortality — compared to placebo. This effectively ended the recommendation for primary prevention aspirin in older adults. Aspirin for secondary prevention (established cardiovascular disease) remains appropriate. The finding has relevance for any longevity-oriented person who was taking aspirin prophylactically without established cardiovascular indication.4
Tier 3: Strong Animal Data, Limited Human Longevity Evidence
Rapamycin: The gold standard of longevity pharmacology in animals, rapamycin (and its analogs, rapalogs) extend lifespan in every model organism tested and in mice even when begun late in life. The longevity medicine community uses it off-label at doses of 2 to 6 mg/week (intermittent weekly dosing designed to inhibit mTORC1 while partially sparing mTORC2 and the immune effects of daily dosing). Human longevity RCT evidence is absent. The PEARL trial (ongoing) is testing low-dose rapamycin in healthy older adults using biological aging biomarkers as endpoints. Safety concerns at clinical immunosuppressive doses (daily dosing for transplant) include infections, impaired wound healing, and metabolic effects that are substantially reduced at intermittent low doses used in longevity contexts.
Acarbose: Perhaps the most overlooked longevity drug candidate. Acarbose is an alpha-glucosidase inhibitor that delays carbohydrate digestion in the small intestine, blunting post-meal glucose and insulin excursions. In the ITP mouse trial, acarbose extended median lifespan by 17 percent in males and 5 percent in females — one of the largest longevity effects seen with any compound in the ITP program. It is inexpensive, generic, has an excellent decades-long safety record (GI side effects are the primary limitation), and has a mechanism entirely complementary to metformin. No longevity-specific human trial has been conducted.5
Evidence Summary Table
| Drug | Animal Longevity Data | Human CV Outcomes | Human Longevity RCT | Off-Label Longevity Use |
|---|---|---|---|---|
| GLP-1 agonists | Moderate | Strong (SELECT, LEADER) | None | Increasing |
| SGLT2 inhibitors | Moderate | Strong (EMPEROR, DAPA) | None | Increasing |
| Metformin | Mixed | Observational only | TAME pending | Widespread |
| Rapamycin | Very strong (ITP) | None | None | Growing |
| Acarbose | Strong (ITP male) | None longevity-specific | None | Minimal |
| Aspirin (primary prev.) | Limited | Negative (ASPREE) | Not recommended | Now discouraged |
References
- 1Lopez-Otin C, et al. "Hallmarks of aging: an expanding universe." Cell. 2023;186(2):243-278. [PubMed]
- 2Lincoff AM, et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT)." NEJM. 2023;389(24):2221-2232. [PubMed]
- 3Barzilai N, et al. "Metformin as a tool to target aging." Cell Metabolism. 2016;23(6):1060-1065. [PubMed]
- 4McNeil JJ, et al. "Effect of aspirin on all-cause mortality in the healthy elderly (ASPREE)." NEJM. 2018;379(16):1519-1528. [PubMed]
- 5Harrison DE, et al. "Acarbose, 17-alpha-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males." Aging Cell. 2014;13(2):273-282. [PubMed]